Summary
The use of cell salvage is recommended when it can be expected to reduce the likelihood of allogeneic (donor) red cell transfusion and/or severe postoperative anaemia. We support and encourage a continued increase in the appropriate use of peri-operative cell salvage and we recommend that it should be available for immediate use 24 h a day in any hospital undertaking surgery where blood loss is a recognised potential complication (other than minor/day case procedures).
Recommendations
1 The use of cell salvage is recommended when it can be expected to reduce the likelihood of allogeneic (donor) red cell transfusion and/or severe postoperative anaemia.
2 We recommend that cell salvage equipment and staff trained to operate it be immediately available 24 h a day in hospitals undertaking surgery where blood loss is a recognised complication.
3 Collection of blood for potential cell salvage ('collect only' mode) should be considered for surgical procedures where blood loss may exceed 500 ml (or > 10% of calculated total blood volume) in adult patients, or > 8 ml.kg À1 (> 10% of calculated total blood volume) in children weighing > 10 kg.
4 Each hospital should have both a nominated clinical lead and a coordinator for cell salvage, who oversee a competence-based training programme for all involved staff, along with ongoing data collection and audit.
5 When the use of cell salvage is proposed in surgery for malignancy or infection, an explanation should be given to the patient of the potential risks and benefits and specific consent should be obtained.
6
The use of leucodepletion filters should be considered during re-infusion of salvaged blood in cancer surgery and when blood is salvaged from an infected surgical field. There is mixed evidence of the benefit of leucocyte depletion filters in obstetrics. What other guideline statements are available on this topic?
These guidelines update previous Association of Anaesthetists guidelines on intra-operative cell salvage published in 2009 [1] . The National Institute for Health and Care Excellence (NICE) published guidelines for intra-operative cell salvage in obstetrics in 2005 [2] and in urology in 2008 [3] . The UK Cell Salvage Action Group has published guidance and other resources [4] . In Australia, the National Blood Authority has published relevant guidance [5] . Most recently, the NICE transfusion guidelines refer to cell salvage [6] .
Why were these guidelines developed?
Introduction
Our previous guideline on this topic was published in 2009, when cell salvage (CS) was relatively underused and devices were only just being introduced into many hospitals [1] . Since then, there has been rapid expansion in its availability and use. The aim of this guideline is to provide a practical series of recommendations to facilitate widespread use.
Although potentially life-saving, allogeneic (donor)
blood is a precious resource with limited supply [7] . It is relatively expensive, and poses potential risks to the patient [8] . There has been much work to try to encour- [6] .
The Association of Anaesthetists has defined significant blood loss as > 500 ml in adults [10] . A recent survey by the UK Cell Salvage Action Group suggests that CS is being used across several specialties, but that some units still face significant barriers, such as lack of staffing, training and funding [11] . Where there is temporary contamination of the surgical field with solutions that may cause red cell lysis, or drugs or substances that should not be given intravenously, then CS should be discontinued and the standard operating room suction system used instead. In most cases, CS may be resumed later following irrigation of the surgical field with saline.
The Working Party suggests that detailed information about CS is given to patients before surgery whenever the use of CS is planned or likely, and that patients are offered an opportunity to discuss the potential advantages and disadvantages of CS with an appropriate clinician.
Organisation of service and education of staff
Cell salvage should be integral to and embedded within surgical and peri-operative practice, and we recommend that CS equipment and staff trained to operate it be immediately available 24 h a day in hospitals undertaking surgery where blood loss is a recognised complication.
There should be a named clinical lead and nominated CS coordinator (e.g. theatre practitioner registered nurse, operating department practitioner/anaesthetic assistant, perfusionist) within the operating theatre department who are responsible for ensuring overall management and facilitation of the hospital CS service.
Every surgical and obstetric unit should have a local guideline/protocol and standard operating procedure in place. These should specify: staff training; patient selection; patient information; prescribing requirements; standards of labelling for the re-infusion bag; checks before transfusion; documentation; adverse incident reporting; quality assurance; and audit, as detailed below. National
Occupational Standards should be referred to [14] . These are broad and generic standards that apply to all personnel involved in CS regardless of professional background.
An adequate number of staff should be trained and skilled in the use of CS to allow service continuity throughout the 24-h period.
Although it is possible to have dedicated CS operators, it is more common for theatre staff or a perfusionist 
Technical aspects
The cell salvage system should be used according to the manufacturers' instructions and should be routinely run in automatic mode if available. There are several different suction devices [18] and different machines [19] 
Obstetrics
Obstetric haemorrhage is a significant cause of maternal mortality and the most report showed an increase in deaths -almost double the rate -from haemorrhage, mainly attributable to abnormal placentation [20] ; it also remains a leading cause of maternal morbidity in the UK [21] . National surveys show that CS is a resource that is being used more frequently in UK obstetric units [22] .
Re-infusion rates and cost effectiveness are variable and directly associated with larger volumes of blood loss [23] .
Despite the growing availability of equipment and safety endorsements for its use, challenges remain in providing CS in an obstetric surgical setting. Haemorrhage associated with emergency operative delivery is often not predictable, rapid and occurs out of hours.
The SALVO trial (cell salvage during caesarean section: a randomised controlled trial) is the largest study to date (n = 3054) examining the role of CS in caesarean section [24] . SALVO did not find a significant difference in donor transfusion rate in caesarean section or a cost benefit argument for routinely setting up a complete collection and retransfusion system. However, institutional level costs are still dependent on case volume, expected levels of blood loss per case and initial investment costs [25] . Use of strategies such as swab washing to improve collection rates should be considered to contribute to the complex analysis of cost effectiveness locally [26] . showed that routine use reduced the transfusion of red cells by 40% [29] .
Blood lost before and after bypass, when the patient is not heparinised, is wasted unless cell salvage is used.
However, during bypass, when the patient is heparinised, cardiotomy suckers are used to collect any blood from the surgical field, which is passed through a filter and returned to the bypass reservoir and then the patient's circulation. There has been some research into the use of CS during bypass, instead of the use of cardiotomy suckers. However, the use of CS during bypass, compared with direct suction into the cardiotomy reservoir, results in depletion of clotting factors and platelets, and is therefore not recommended.
After bypass, around 500-1000 ml of blood will be left in the bypass circuit and reservoir. It is commonplace to return this unprocessed blood to the patient, but there is some evidence that processing this by separation and washing of red cells using a cell salvage system, thereby concentrating the red cells and increasing the haematocrit before re-infusion, may be beneficial in terms of reduction in requirement for allogeneic blood [30] .
However, centrifugation of residual bypass pump blood is also effective in increasing the haematocrit before re-infusion [31] . Other blood concentrating devices have not been shown to be effective [32] . We recommend that cell salvage, if already in progress, be used to concentrate residual bypass pump blood before re-infusion;
alternatively, the use of centrifugation under these circumstances is reasonable [31] .
Some centres in the UK routinely use cell salvage throughout cardiac surgery. However, there is conflicting evidence for cost effectiveness during lower-risk surgery such as primary coronary bypass or single valve surgery [33] . We recommend the use of cell salvage, at least in 'collect only' mode, for all cardiac surgery. If blood collected is > 500 ml, this can be processed and returned to the patient. Cell salvage is recommended whenever cardiac surgery is performed without the use of bypass ('off-pump').
The use of cell salvage during open aortic surgery is also well established. It has been shown to be safe, and a meta-analysis has shown that the use of cell salvage may reduce the risk of red cell transfusion by 37% in patients undergoing elective abdominal aortic aneurysm (AAA) repair [34] . A study in emergency AAA surgery showed that up to three units of red cells may be saved per patient and that hospital mortality was reduced [35] . We recommend that cell salvage is used
routinely for all open aortic surgery, and considered for all vascular surgery where > 500 ml blood loss is expected.
Orthopaedics and trauma
Data from 19 years and more than 2 million total joint arthroplasties revealed that there was an increase in red cell transfusion until 2011 and that this was associated with an increase in morbidity [36] . In a meta-analysis of RCTs that included hip and knee arthroplasties, intraoperative CS significantly reduced red cell transfusion exposure rate and the volume of allogeneic red cells transfused [37] .
Intra-operative CS should be considered in all patients undergoing orthopaedic or trauma surgery when blood loss is expected to be > 500 ml. If bone cement is used, then CS should not be used while cement is being applied and can be resumed when the cement is fully set. For revision surgery, when metalwork may be in situ, such as previously instrumented spinal surgery, there is evidence that standard 40 micron filters do not eliminate the smallest fragments of titanium, so caution should be exercised [38] . However, we still recommend that CS is considered in such cases, with the proviso that standard suction is used until the surgical field has been irrigated and all metal fragments removed. Also, CS should not be [39] . It concluded that CS in this setting reduces blood transfusion and is cost effective. Prospective data for 30 patients [40] undergoing pelvic acetabular fracture fixation found a mean blood loss of 1233 ml and an average of 388 ml retransfused through CS; only 47% of patients required allogeneic transfusion. In a combat hospital, a CS feasibility study concluded that CS was most successful in patients with gunshot wounds and cavity injuries compared with limb or blast injuries [41] .
In a dedicated trauma/emergency operating theatre, we recommend that a CS machine and staff trained to operate it should be immediately available at all times.
Paediatrics
Complications of allogeneic blood transfusion in children and infants may be more common than in adults [42] .
Pre-operative autologous donation in children has both practical and complex logistical problems that make it costly and of uncertain benefit [43] . Cell salvage should be used as part of a comprehensive Patient Blood Management programme [44] . Cell salvage is used most frequently in spinal surgery (larger children or adolescents), during cardiac surgery [45] , liver transplantation and cranio-facial surgery [46] . Cell salvage may replace or reduce the transfusion of allogeneic blood, depending on the clinical circumstances.
The expected blood loss (EBL) to blood volume (BV) ratio (EBL/BV) that might mandate the use of CS varies in the paediatric literature from 10% to 40%, and this reflects local practice and equipment availability. The
Working Party recommends that CS should be considered at least in 'collect only' mode when blood loss > 8 ml.kg À1 (equivalent to approximately > 10% of total blood volume) is anticipated and the child's weight is > 10 kg [47] .
Some CS devices collect aliquots of blood in a bowl that must be filled before washing to retrieve the blood, A Cochrane review analysed 29 trials on postoperative cell salvage after cardiac and orthopaedic surgery [12] , and showed a 41% reduction in allogeneic red cell transfusion (RR 0.59; 95%CI 0.48-0.73).
Re-infusion of recovered blood, with or without washing, after orthopaedic procedures is safe and economical [51] . Unwashed postoperative blood salvage may be used after orthopaedic surgery, particularly total knee arthroplasty, and has been found to reduce exposure to allogeneic red cell transfusion [6] .
After cardiac surgery, blood collected via the chest drains must be processed through a cell salvage system before re-infusion due to accumulation of fat and other contaminants that are removed by the cell salvage process. We recommend that (washed) CS be considered in patients who bleed > 100 ml.h À1 in the first 6 h after cardiac surgery, and whenever resternotomy is required for haemorrhage [4, 5] .
Cancer surgery
Despite theoretical concern, there is no absolute contraindication to CS in cancer surgery. Its use is controversial because malignant cells are often present in the operative field, can be found in salvaged blood and may, theoretically, metastasise after re-infusion. Circulating malignant cells are often present in cancer patients undergoing surgery, regardless of CS use, and very few of these cells are thought capable of causing metastases [52] . The number of malignant cells in salvaged blood can be reduced by the use of LDFs, with no apparent adverse effect on the quality of the product [52] . The use of LDFs has not been shown to be associated with either bradykinin or leukotriene generation in cell-salvaged blood [53] . Cell salvage may reduce or eliminate exposure to allogeneic blood, which has been associated with immunosuppression and cancer recurrence [54] . One major disadvantage of LDFs is that the rate of flow through them is considerably slower, and therefore clinicians may need to assess the benefit of quicker transfusion without a LDF vs. its use.
In summary, despite theoretical risks and benefits, there is no conclusive evidence that CS can induce metastases or affect cancer prognosis [55] . The theoretical risk of inducing metastatic spread (unproven) is offset by reduced allogeneic transfusion and immunomodulation, which is proven. As a result, many clinicians do offer cell salvage to patients undergoing major cancer surgery. The Working Party recommends that potential risks and benefits should be discussed with patients before cancer surgery, and specific consent obtained.
Infected and contaminated fields
There is no absolute contraindication to CS in this setting.
Its use is, however, controversial, because CS might (theoretically) worsen sepsis by introducing infective agents and toxins recovered in the operative field. Conversely, CS reduces exposure to allogeneic blood, which may increase the incidence of postoperative infection through immunomodulation [56, 57] . Washing of collected blood and the use of LDFs removes most bacteria, but this effect is probably dependent on the level of contamination [58] . There is no conclusive evidence that CS worsens sepsis, prognosis or the risk of other specific complications when used in contaminated fields, including major trauma surgery.
We recommend that the use of cell salvage in cancer surgery and infected fields should be considered on a case by case basis. Whenever possible, patients in whom cell savage is used should be counselled and asked whether they consent to the procedure being used. Leucodepletion filters should be used for blood re-infusion.
